Damora Therapeutics, Inc. (DMRA): who owns it and who trades it
As of Nov 16, 2026, DMRA insiders reported 4 open-market sales worth $30.7K and 1 purchase worth $253K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Hans T. Schambye (CEO), with $15K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Damora Therapeutics
From the latest filingsOverall: more buying than selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns DMRA
102 funds and institutions reported DMRA shares worth $1.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 9.23M | 15.31% | $240M | +2% |
| Fairmount Funds Management LLC | 8.71M | 14.45% | $227M | No change |
| Avoro Capital Advisors LLC | 3.78M | 6.27% | $98.4M | No change |
| Venrock Adviser, LLC | 3.60M | 5.98% | $93.7M | No change |
| BlackRock, Inc. | 3.16M | 5.24% | $82.2M | +1322% |
| Fcpm III Services B.v. | 2.44M | 4.05% | $63.5M | No change |
| Ra Capital Management, L.P. | 2.40M | 3.98% | $62.4M | No change |
| Viking Global Investors LP | 2.31M | 3.83% | $60.1M | No change |
| Jupiter Topco LLC | 2.28M | 3.79% | $59.3M | New |
| JPMorgan Chase & Co | 2.06M | 3.41% | $49.8M | New |
| Remedium Capital Partners, LLC | 2.05M | 3.39% | $53.2M | No change |
| Commodore Capital LP | 1.94M | 3.22% | $50.4M | No change |
| Braidwell LP | 1.62M | 2.69% | $42.1M | +81% |
| Bellevue Group AG | 1.62M | 2.68% | $42.1M | -30% |
| State Street Corp | 1.55M | 2.56% | $40.2M | +740% |
| A16z Capital Management, L.L.C. | 1.24M | 2.05% | $32.2M | No change |
| Balyasny Asset Management L.P. | 1.23M | 2.04% | $32M | -15% |
| Perceptive Advisors LLC | 1.22M | 2.03% | $31.8M | No change |
| Wellington Management Group LLP | 1.06M | 1.75% | $27.5M | No change |
| California State Teachers Retirement System | 1.05M | 1.75% | $40.5M | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, DMRA insiders reported $253K of open-market purchases and $30.7K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Jennifer Jarrett | CEO | Purchase | 12,500 | $20.23 | $253K | Form 4 |
| Jul 6, 2026 | Garrett Winslow | General Counsel | Sale | 245 | $29.98 | $7.3K | Form 4 |
| Jan 2, 2026 | Hans T. Schambye | CEO | Sale | 700 | $21.38 | $15K | Form 4 |
| Jan 2, 2026 | Garrett Winslow | General Counsel | Sale | 255 | $21.38 | $5.5K | Form 4 |
| Jan 2, 2026 | Lori Firmani | CFO | Sale | 135 | $21.41 | $2.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jennifer Jarrett | Director, President and CEO, Director | $253K | – | Sep 25, 2026 |
| Hans T. Schambye | Chief Executive Officer, Director | – | $15K | Jan 2, 2026 |
| Garrett Winslow | General Counsel | – | $12.8K | Jul 6, 2026 |
| Lori Firmani | Chief Financial Officer | – | $2.9K | Jan 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DMRA short interest
Moderate short interest. 7.6% of DMRA shares are sold short: about 1 share in 13. Over the last 12 reports the number of shares short went up 263%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.69M DMRA shares were sold short, 7.6% of the shares outstanding, down 9.0% from the report before. At the average daily volume of 439,761 shares, buying them all back would take about 10.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.69M | 7.60% | -9% | 439,761 | 10.7 |
| Oct 15, 2026 | 5.15M | 8.35% | +9% | 461,896 | 11.2 |
| Sep 30, 2026 | 4.73M | 7.67% | No change | 985,492 | 4.8 |
| Sep 15, 2026 | 4.73M | 7.67% | +15% | 552,562 | 8.6 |
| Aug 31, 2026 | 4.13M | 6.69% | -13% | 311,356 | 13.3 |
| Aug 14, 2026 | 4.74M | 7.68% | -3% | 349,370 | 13.6 |
| Jul 31, 2026 | 4.89M | 8.11% | +4% | 417,727 | 11.7 |
| Jul 15, 2026 | 4.69M | 7.77% | +31% | 580,045 | 8.1 |
| Jun 30, 2026 | 3.57M | 5.92% | +172% | 1.36M | 2.6 |
| Jun 15, 2026 | 1.31M | 2.17% | -7% | 389,269 | 3.4 |
| May 29, 2026 | 1.40M | 2.33% | +9% | 338,844 | 4.1 |
| May 15, 2026 | 1.29M | 2.14% | +8% | 418,102 | 3.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Damora Therapeutics company events
Damora Therapeutics filed 11 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, auditor). The latest was on Jul 20, 2026.
- Jul 20, 2026AgreementDamora Therapeutics, Inc., a Cayman Islands exempted company, entered into indemnification agreements with each of its directors and executive officers, which replaced and superseded any previous indemnification agreements between the Company and each such individual. Filing
- Jun 17, 2026VoteReported shareholder vote results. Filing
- May 4, 2026LeadershipThe Board of Directors of Damora Therapeutics, Inc. determined that, effective as of May 1, 2026, Lori Firmani would cease serving as the Company’s Chief Financial Officer. Filing
- Apr 20, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Mar 23, 2026LeadershipChief Executive Officer Appointment The Board of Directors of Damora Therapeutics, Inc. appointed Jennifer Jarrett as President and Chief Executive Officer of the Company, effective as of March 30, 2026. Filing
- Mar 10, 2026ResultsReleased financial results. Filing
- Feb 11, 2026AgreementGalecto, Inc. entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC, as the representatives of the several underwriters named therein, relating to the offer and sale of 14,473,685 shares of the Company’s common stock, par value $0.00001 per share, at a public offering… Filing
- Feb 10, 2026LeadershipThe Board of Directors of Galecto, Inc. determined that, effective as of 12:01 a.m. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Jan 6, 2026LeadershipThe Company announced that the board of directors of the Company appointed Sherwin Sattarzadeh as the Company’s Chief Operating Officer, effective as of January 5, 2026. Filing
- Dec 9, 2025RulesAmended an earlier report. Changed its bylaws or articles. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Damora Therapeutics financials
Famous investors that hold DMRA
3 of the 50 well-known investors we track reported holding DMRA in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $25.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 1.21M | $25.7M | 0.1% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 388,042 | $8.3M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 266,211 | $5.7M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Damora Therapeutics, Inc. (DMRA) stock
Who owns the most DMRA stock?
The largest reported owner of Damora Therapeutics, Inc. (DMRA) is FMR LLC (Fidelity), with 15.3% of the company. In total, 102 funds and institutions reported holding DMRA at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are DMRA insiders buying or selling?
In the last 12 months, DMRA insiders reported 1 open-market purchase worth $253K and 4 sales worth $30.7K. The latest trade was on Sep 25, 2026. See every trade.
What is the short interest in DMRA?
As of Oct 30, 2026, 4.69M DMRA shares were sold short, 7.6% of the shares outstanding, down 9.0% from the report before. At the average daily volume of 439,761 shares, buying them all back would take about 10.7 trading days (days to cover). See the history.
Which famous investors hold DMRA?
3 of the 50 well-known investors we track reported DMRA in their latest 13F filing, including Andreas Halvorsen, Ken Griffin, Israel Englander. The largest position is worth $25.7M. See all holders.
Executive pay
Damora Therapeutics's chief executive was paid a total of $1.3M for the year ended Dec 31, 2025, down 9% from $1.4M the year before. In the last 12 months, Damora Therapeutics's executives and directors bought $253K of stock on the open market and sold $30.7K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.